Physician profile
Jared Jackson
NPI 1730476730
$3,429.74
in general payments reported to CMS, 2019-2025
28 companies · $839 in 2025
The $839 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $123 · 2021: $130 · 2022: $806 · 2023: $527 · 2024: $624 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,980 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.43 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $611.03 | 2021-2023 | Tepezza |
| Abbvie INC. | $442.40 | 2022-2025 | |
| Alcon Vision LLC | $427.82 | 2021-2025 | Argos, Clareon Panoptix Pro, Tryptyr |
| Amgen INC. | $389.79 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $213.58 | 2019-2024 | Cequa |
| Glaukos Corporation | $186.41 | 2023-2025 | Istent Infinite, Idosetr, Glaucoma Accessory Products |
| Ivantis, INC | $136.52 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $121.35 | 2024 | Tezspire |
| Dompe US, INC. | $113.35 | 2019-2025 | Oxervate |
| Optos, INC. | $93.47 | 2022 | |
| Sight Sciences, INC. | $81.82 | 2019-2020 | |
| Allergan, INC. | $71.69 | 2020 | |
| Oyster Point Pharma, INC. | $65.87 | 2022-2023 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $63.95 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $54.30 | 2024-2025 | Scoutpro Osmolarity System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $50.62 | 2023-2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $44.45 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $43.84 | 2019-2020 | |
| Shire North American Group INC | $36.83 | 2019 | |
| Ani Pharmaceuticals, INC. | $33.64 | 2024 | Purified Cortrophin Gel |
| Eyevance Pharmaceuticals LLC | $29.09 | 2019-2021 | |
| Rxsight INC | $25.06 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Boston Scientific Corporation | $23.44 | 2024 | Rezum Generator |
| Thea Pharma INC. | $18.51 | 2022 | |
| Ocular Therapeutix, INC. | $15.99 | 2021 | |
| Heidelberg Engineering, INC. | $13.54 | 2025 | Spectralis |
| Omeros Corporation | $13.33 | 2019 | |
| Katena Products, INC. (Dba Corza Medical) | $8.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.